Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.

Bottles coronavirus vaccine. sars-cov-2 / COVID-19. Some ampoules with ncov-2019 vaccine in a box. to fight the coronavirus pandemic.
Moderna raised its 2020 cash burn guidance, primarily to cover mRNA-1273 manufacturing costs • Source: Shutterstock

Moderna, Inc.’s initial deals for purchases of mRNA-1273, its messenger RNA (mRNA) vaccine against SARS-CoV-2, set a relatively high per-dose price of $32-$37. However, these first deals with smaller governments total just $400m to date, as opposed to the multibillion-dollar deals the US has made with other vaccine makers, and in those kinds of high-volume deals the company said its price per dose is likely to be lower.

Pfizer Inc. and BioNTech SE effectively set a $19.50 price per dose last month with the $1.95bn deal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains